Please assess the completion status of the following clinical trial:

Trial Title: Prospective Study With Adjunctive Once Daily Topical Nepafenac 0.3% Versus Placebo

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects, 18 and older subjects with visually significant cataracts and were to undergo phacoemulsification with implantation of an intracapsular positioned intraocular lens.~Exclusion Criteria:~* previous uveitis (\<1 year) previous anterior segment intraocular surgery hypersensitivity or allergy to NSAIDs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- nepafenac 0.3% (Type: EXPERIMENTAL): nepafenac 0.3% ophthalmic solution dosed once daily
- Saline Solution (Type: PLACEBO_COMPARATOR): sterile saline drops with a pH approximately of 7.0 and osmolality of 290 mOsm/kg, dosed at once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).